Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:15p JOHNSON & JOHNSON : Dr Koul appointed IMTECH Director
10:18a JOHNSON & JOHNSON : R.I. Commerce considering $12.7M in incentives for four firm..
01/20 JOHNSON & JOHNSON : Trump taps Jets owner Woody Johnson as UK ambassador
01/20 JOHNSON & JOHNSON : R.I. Gov. Raimondo strikes a balance in 2 speeches on 1 day
01/20 JOHNSON & JOHNSON : Jets owner johnson is trump's choice as ambassador to u.k.
01/20 JOHNSON & JOHNSON : Ethicon Announces Acquisition of Megadyne Medical Products, ..
01/20 JOHNSON & JOHNSON : New York Jets owner Woody Johnson set to be US ambassador to..
01/20 JOHNSON & JOHNSON : Trump appears to announce Jets owner as Britain ambassador T..
01/20 JOHNSON & JOHNSON : Donald Trump picks New York Jets owner Woody Johnson as U.S...
01/19 JOHNSON & JOHNSON : New York Jets owner Woody Johnson to be US ambassador to UK
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:17a JOHNSON & JOHNSON EARNINGS PREVIEW : Don't Expect Big Surprises
01/20 Why Gilead Is Undervalued
01/20 The Most Important Keys To Celgene's Pipeline
01/20 BOEING : Ready To Take Off... You Haven't Seen Anything Yet
01/20 J & J's Ethicon unit buys electrosurg device maker Megadyne Medical Products
Advertisement
Financials ($)
Sales 2016 72 123 M
EBIT 2016 22 002 M
Net income 2016 16 672 M
Finance 2016 16 903 M
Yield 2016 2,75%
P/E ratio 2016 19,32
P/E ratio 2017 17,13
EV / Sales 2016 4,07x
EV / Sales 2017 3,83x
Capitalization 310 549 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
SANOFI-1.66%104 532
More Results